Chemotherapy as a tablet instead of an intravenous infusion
New production method for solid dispersions of docetaxel and paclitaxel.
On 29 March 2017, Dutch pharmacist Emilia Sawicki will be defending her doctoral thesis in which she describes how some anticancer medicines can be formulated in such a way that patients take chemotherapy orally as a tablet, rather than as an intravenous infusion at the hospital. One of the anticancer medicines for which she developed a tablet formulation is the widely used drug docetaxel. The formulation is a tablet which is made as a ‘solid dispersion’, and was co-developed by Sawicki at the Slotervaart Medical Centre and the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital in Amsterdam. The discovery has already progressed to an advanced stage in the clinical development: shortly, a clinical trial will be opened at several Dutch hospitals where patients with prostate cancer will be treated with the solid dispersion tablet of docetaxel.
Anticancer medicines are increasingly being used as capsules or tablets. Oral medicines are more patient-friendly than the traditional way of administration the chemotherapy as an intravenous infusion. Patients can take the medicine at home as a tablet and no longer have to travel to a hospital to receive chemotherapy. One of the requirements is that the anticancer medicine dissolves in water in order to be effectively taken up in the blood. Dissolution is better if a ‘solid dispersion’ is used: a mixture of tiny particles of powdered medication, which dissolve faster and better in water than larger particles, such as crystalline powders.
In her doctoral thesis ‘Solid dispersions in oncology: a solution to solubility-limited oral drug absorption’, Sawicki describes a new production method for solid dispersions of docetaxel and paclitaxel, two anticancer medicines that are often prescribed to patients with prostate cancer, breast cancer and lung cancer. For example, docetaxel is prescribed approximately 24,000 times a year to cancer patients in the Netherlands. As a solid form docetaxel and paclitaxel are not well absorbed in the blood. This is because they are very poorly soluble in water and because they are broken down by enzymes in the gastrointestinal tract and liver. The solid dispersion method increases the dissolution of docetaxel and paclitaxel 40 to 100 times and when co-administered with enzyme inhibitor ritonavir these anticancer medicines are then effectively absorbed in the blood. As a result, many patients experience a highly promising anticancer effect.
Moreover, the production method for the solid dispersion tablet of docetaxel is suitable to supply the medicine on a large scale and this makes it possible to conduct large clinical trials. Amsterdam-based biopharmaceutical company Modra Pharmaceuticals is launching shortly several clinical trials with the solid dispersion tablet of docetaxel.
In addition, Sawicki also used the solid dispersion technique to develop a tablet formulation of elacridar, a medicine predominantly used in studies focusing on brain tumours, since elacridar promotes the absorption of other anticancer medicines in the brain.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance